Global Information
회사소개 | 문의 | 비교리스트

소화관 관련 각종 제휴 계약 : 계약 조건 및 합의 내용

Global Gastrointestinal Partnering 2014-2020: Deal trends, players and financials

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행일 2020년 10월 상품 코드 250304
페이지 정보 영문 300+ Pages
가격
US $ 3,495 ₩ 4,033,000 PDF by E-mail (Single User License)
US $ 5,245 ₩ 6,052,000 PDF by E-mail (Multi User License - 2 to 5 Users)
US $ 10,495 ₩ 12,111,000 PDF by E-mail (Single Site License - 6+ Users)
US $ 17,495 ₩ 20,189,000 PDF by E-mail (Global License)


소화관 관련 각종 제휴 계약 : 계약 조건 및 합의 내용 Global Gastrointestinal Partnering 2014-2020: Deal trends, players and financials
발행일 : 2020년 10월 페이지 정보 : 영문 300+ Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

소화관(Gastrointestinal) 관련 각종 제휴 계약에 대해 조사 분석하고, 최근의 각종 계약 동향, 대규모 계약 및 대형 의약품 사업자의 계약 개요, 계약 구분·개발 단계·기술 구분·적응증별 디렉토리 등을 전해드립니다.

개요

제1장 서론

제2장 소화관 관련 각종 계약 동향

  • 서론
  • 지난 몇 년간의 소화관 관련 제휴
  • 대형 제약회사의 계약 활동
  • 소화관 관련 사업에 적극적이지 않은 대형 제약회사
  • 소화관 관련 제휴 : 계약 유형별
  • 소화관 관련 제휴 : 산업 부문별
  • 소화관 관련 제휴 : 개발 단계별
  • 소화관 관련 제휴 : 기술 유형별
  • 소화관 관련 제휴 : 적응증별
  • 평균 계약기간

제3장 주요 계약

  • 서론
  • 주요 계약 : 거래액별
  • 대형 제약회사 관련 주요 계약

제4장 대형 제약회사의 계약

  • 서론
  • 대형 제약회사의 제휴 계약 이용법
  • 기업 개요

제5장 계약 디렉토리

  • 서론
  • 계약 유형별
    • 자산 구입
    • 대형 제약 기업의 아웃라이선싱
    • 공동 개발
    • 공동 R&D
    • 공동 판매
    • 서비스 계약
    • 공동 프로모션
    • 개발
    • 유통
    • 주식 구입
    • 라이선싱
    • 소송
    • 대출
    • 제조
    • 마케팅
    • 옵션
    • 프로모션
    • 연구
    • 화해 관련
    • 서브 라이선스
    • 공급
    • 기술 이전
    • 종료
  • 개발 단계별
    • Discovery
    • 제제 설계
    • 출시
    • 단계 I
    • 단계 II
    • 단계 III
    • 전임상
    • 규제
  • 기술 유형별
    • 항체
    • 생물학적 화합물
    • 세포 치료
    • 디바이스
    • 진단
    • Discovery Tool
    • 약물 전달(Drug Delivery)
    • 가능화 기술(Enabling Technology)
    • 설비
    • 장비
    • 유전체학(Genomics)
    • 이미징
    • 천연 제품
    • 올리고뉴클레오티드(Oligonucleotide)
    • 펩티드
    • 프로테오믹스
    • Research services
    • Research supplies
    • 스크리닝
    • 소분자
    • 소프트웨어 툴
    • 줄기세포

제6장 소화관 관련 계약 : 적응증별

  • 서론
  • 적응증별
    • 소화관
    • 맹장염
    • 셀리악병
    • 식도 역류
    • 식도염
    • 위염
    • 위장염
    • 치질(치핵)
    • 헤르니아
    • 염증성 장질환
    • 크론병
    • 궤양성 대장염
    • 과민성 장증후군
    • 흡수 불량
    • 영양 불량
    • 췌장염
    • 소화성궤양
    • 위궤양
    • 복통
    • 복수
    • 배변
    • 변비
    • 설사
    • 소화불량
    • 연하곤란
    • 황달
    • 구토

제7장 제휴 기회

  • 온라인 파트너링
  • 파트너링 이벤트
  • 관련 자료

부록

도표

LSH 12.09.19

The Global Gastrointestinal Partnering 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies

Global Gastrointestinal Partnering 2014 to 2020 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Gastrointestinal partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Gastrointestinal partnering agreement structure

Gastrointestinal partnering contract documents

Top Gastrointestinal deals by value

Most active Gastrointestinal dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.

The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gastrointestinal deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gastrointestinal deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2014. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.

Report scope

Global Gastrointestinal Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Gastrointestinal trends and structure of deals entered into by leading companies worldwide.

Global Gastrointestinal Partnering 2014 to 2020 includes:

  • Trends in Gastrointestinal dealmaking in the biopharma industry since 2014
  • Analysis of Gastrointestinal deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Gastrointestinal deal contract documents
  • Comprehensive access to over 420 Gastrointestinal deal records
  • The leading Gastrointestinal deals by value since 2014
  • Most active Gastrointestinal dealmakers since 2014
  • The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.

In Global Gastrointestinal Partnering 2014 to 2020, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Gastrointestinal Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 420 gastrointestinal deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Gastrointestinal Partnering 2014 to 2020 provides the reader with the following key benefits:

  • In-depth understanding of Gastrointestinal deal trends since 2014
  • Access Gastrointestinal deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Gastrointestinal partner companies
  • Comprehensive access to over 420 links to actual Gastrointestinal deals entered into by the world's biopharma companies
  • Indepth review of Gastrointestinal deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Gastrointestinal opportunities
  • Uncover companies actively partnering Gastrointestinal opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gastrointestinal dealmaking

  • 2.1. Introduction
  • 2.2. Gastrointestinal partnering over the years
  • 2.3. Gastrointestinal partnering by deal type
  • 2.4. Gastrointestinal partnering by industry sector
  • 2.5. Gastrointestinal partnering by stage of development
  • 2.6. Gastrointestinal partnering by technology type
  • 2.7. Gastrointestinal partnering by therapeutic indication

Chapter 3 -Financial deal terms for Gastrointestinal partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Gastrointestinal partnering
  • 3.3. Gastrointestinal partnering headline values
  • 3.4. Gastrointestinal deal upfront payments
  • 3.5. Gastrointestinal deal milestone payments
  • 3.6. Gastrointestinal royalty rates

Chapter 4 - Leading Gastrointestinal deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Gastrointestinal partnering
  • 4.3. List of most active dealmakers in Gastrointestinal
  • 4.4. Top Gastrointestinal deals by value

Chapter 5 - Gastrointestinal contract document directory

  • 5.1. Introduction
  • 5.2. Gastrointestinal partnering deals where contract document available

Chapter 6 - Gastrointestinal dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Gastrointestinal therapeutic target

Appendices

  • Appendix 1 - Directory of Gastrointestinal deals by company A-Z 2014 to 2020
  • Appendix 2 - Directory of Gastrointestinal deals by deal type 2014 to 2020
  • Appendix 3 - Directory of Gastrointestinal deals by stage of development 2014 to 2020
  • Appendix 4 - Directory of Gastrointestinal deals by technology type 2014 to 2020
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering
  • Table of figures
  • Figure 1: Gastrointestinal partnering since 2014
  • Figure 2: Gastrointestinal partnering by deal type since 2014
  • Figure 3: Gastrointestinal partnering by industry sector since 2014
  • Figure 4: Gastrointestinal partnering by stage of development since 2014
  • Figure 5: Gastrointestinal partnering by technology type since 2014
  • Figure 6: Gastrointestinal partnering by indication since 2014
  • Figure 7: Gastrointestinal deals with a headline value
  • Figure 8: Gastrointestinal deals with upfront payment values
  • Figure 9: Gastrointestinal deals with milestone payment
  • Figure 10: Gastrointestinal deals with royalty rates
  • Figure 11: Active Gastrointestinal dealmaking activity- 2014 to 2020
  • Figure 12: Top Gastrointestinal deals by value since 2014
Back to Top
전화 문의
F A Q